Relapsed or Refractory Diffuse Large B-cell Lymphoma Case

Author: Dr. Pallavi Ganguli PGY-4 Hematology, Queen’s University
Reviewer: Dr. Robert Kridel, MD, MPH, PhD, Clinician Scientist, Princess Margaret Cancer Centre

Learning Objectives:

As the end of this self-assessment module, participants should be able to:

1. Describe novel therapies for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients ineligible for autologous stem cell transplantation.
2. Describe the mechanism of action of tafasitamab.
3. Describe adverse effects associated with the use of tafasitamab and polatuzumab.
4. Describe the most common hematologic adverse effects of axicabtagene ciloleucel.
5. Describe therapies used for cytokine release syndrome related to axicabtagene ciloleucel.

Scientific Planning Committee

Dr. Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None